

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 16 2001

APPLICANTS: Wright *et al.*

ASSIGNEE: GENESENSE TECHNOLOGIES INC.

SERIAL NUMBER: 09/296,264

EXAMINER: M. M. Schmidt, Ph.D. TECH CENTER 1600/2300

FILING DATE: April 22, 1999

ART UNIT: 1635

FOR: NEUROPILIN ANTISENSE OLIGONUCLEOTIDE SEQUENCES AND METHODS OF USING
SAME TO MODULATE CELL GROWTH

9 / Revoc.
w/P.O.A.



January 9, 2001
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application is the following document:

- ☒ Revocation by Assignee and New Power of Attorney (2 pg.); and
☒ Return Postcard.

Applicants believe that no additional fees are due in connection with this submission. However, the Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 21892-006A. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,

Ivor R. Elrif, Reg. No. 39,529
Shelby J. Walker, Reg. No. 45,192
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Express Mail Label No.: E 05148122US

Date of Deposit: January 9, 2001

Attorney Docket No. 21892-006A (GS-6A)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 16 2001

TECH CENTER 1600/2300

APPLICANTS: Wright *et al.*

ASSIGNEE: GENESENSE TECHNOLOGIES INC.

SERIAL NUMBER: 09/296,264

EXAMINER: M. M. Schmidt, Ph.D.

FILING DATE: April 22, 1999

ART UNIT: 1635

FOR: NEUROPILIN ANTISENSE OLIGONUCLEOTIDE SEQUENCES AND METHODS OF
USING SAME TO MODULATE CELL GROWTH

Assistant Commissioner for Patents
Washington, D.C. 20231

REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

GENESENSE TECHNOLOGIES INC., a company and assignee of the above-identified application U.S.S.N. 09/296,264, filed April 22, 1999, assignment recorded June 16, 1999 at Reel/Frame 010034/0027, hereby revokes any and all former powers of attorney and appoints:

Attorney or Agent	Registration No.	Attorney or Agent	Registration No.
Kevin N. Ainsworth	39,586	Robert Klauszinski	42,742
Ingrid A. Beattie	42,306	Kristin E. Konzak	44,848
Naomi Biswas	38,384	Cynthia Kozakiewicz	42,764
David F. Crosby	36,400	William A. Marino	44,219
James G. Cullem	43,569	Barry J. Marenberg	40,715
Brett N. Dorny	35,860	A. Jason Mirabito	28,161
Marianne Downing	42,870	Michel Morency	Limited Recognition
Ivor R. Elrifi	39,529	Bradley J. Olson	40,750
Heidi A. Erlacher	45,409	Mike Renaud	44,299
Christina M. Gadiano	37,628	Brian Rosenbloom	41,276
John A. Harre	37,345	Carol H. Peters	45,010
Shane Hunter	41,858	Thomas M. Sullivan	39,392
David E. Johnson	41,874	Howard Susser	33,556
Kris Kalidindi	41,461	Shelby J. Walker	45,192
Christina Karnakis	45,899	Martin M. Zoltick	35,745

all of MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO PC, One Financial Center, Boston, Massachusetts 02111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the above-identified patent.

Express Mail Label: 05148122US
Date of Deposit: January 9, 2001

SEND CORRESPONDENCE TO:

Ivor R. Elrifi
Mintz Levin
One Financial Center
Boston, MA 02111

DIRECT TELEPHONE CALLS TO:

Ivor R. Elrifi, or
Michel Morency
(617) 542-6000

GENESENSE TECHNOLOGIES INC. certifies under 37 C.F.R. § 3.73(b) that it is the Assignee of the entire right, title and interest in the patent identified above by virtue of assignments of the patent identified above.

I, the undersigned, am empowered to act on behalf of the Assignee. Acting on behalf of the Assignee, I have reviewed all the documents in the chain of title of the patent identified above and, to the best of my knowledge and belief, title is in the Assignee identified above.

I, the undersigned, hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the patent.

Please charge any fee or any fee deficiency occasioned by this document to Deposit Account No. 50-0311, Reference No. 21892-006A.

Respectfully submitted,



Shane Ellis
Corporate Secretary
GENESENSE TECHNOLOGIES INC.
7100 Woodbine Avenue, Suite 215
Markham, Ontario
Canada L3R 5J2

Date: _____, 2000

TR\DOCS\1378934.1(TJZQ011.DOC)